Harris & Harris Group, Inc.

Great news! Our portfolio company Bridgelux has entered into a definitive agreement to be acquired by an investment group. For more information:

We've got more exciting news to share regarding portfolio company, OpGen! The company has gained a $6 million investment from Merck Global Health Innovation, along with the acquisition of AdvanDx, a developer of advanced molecular diagnostic products. To learn more about this news, check out the news release:

Portfolio company, OpGen, enters into strategic agreement with Fluidigm to develop multi-drug resistance testing kits & equipment. Check out the release here:

Our portfolio company, D-Wave Systems Inc., has broken the 1000 #Qubit #QuantumComputing barrier! For more information please check out the news release:

Harris & Harris Group, Inc. Our own Doug Jamison is set to speak this evening on bringing early-stage innovations to market at TechConnect Conference. http://bit.ly/1KTkN0d

We're excited to share that our portfolio company, OpGen, a molecular diagnostics company, announced yesterday the pricing of its initial public offering and has raised over $17 million! For more information be sure to check out the press release:

Our own Misti Ushio commented in a recent article for Agri-View saying, Agriculture is well positioned to take advantage of the enormous investment in life-science tools and technology developed initially for the healthcare industry. To hear more of Misti's thoughts on the future of agriculture and life sciences check out the article:

Our latest blog post talks about our newest portfolio company ORIG3N and how this early stage company is building early revenue. Check it out here to learn more:

What is on the horizon for NY life science? Our EVP Misti Ushio discusses growth and change March 12th at the Xconomy Xchange. #xcondisrupt

Check out the latest blog post published by our portfolio company, HZO, to learn what attracted us to invest in the company!

Great news! Our portfolio company D-Wave has raised an additional $29 million in funding. The additional investment dollars come as a result of the company's continued progress and leadership in quantum computing and will help accelerate the development of the company's software and hardware.

What does the State of the Union address have to do with our portfolio company TARA Biosystems? Check out this article from Xconomy to find out!

Our CEO Doug Jamison spoke with CFO Thought Leader about the return of the small IPO, as well as the many early stage opportunities within the Harris & Harris Group portfolio. Check out the full interview to learn more!